Patient-derived organoids (PDOs) are a promising in vitro model. They mimic the TME, gene expression, and cell types of original cancer tissues. PDOs have been successfully developed from various cancers, including BC. In this review, we focused on the value and l...
Boretto, M., Maenhoudt, N., Luo, X.et al.Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.Nat Cell Biol21, 1041–1051 (2019). https://doi.org/10.1038/s41556-019-0360-z ...
The recent advances inin vitro3D culture technologies, such as organoids, have opened new avenues to improve basic and clinical cancer research. Up to now, highly efficient establishment of organoids can be achieved from both normal and malignant patient tissues. ...
The article examines patient-derived non-small cells lung cancer (NSCLC) organoids (PDO) and their drug screening applications. Also cited are the possible use of PDOs in personalized cancer therapy, the creation of living NSCLC organoids biobank, and the anticancer a...
Patient-derived Organoids as a Tool for Advancing Precision Immuno-oncology The application of three-dimensional (3D) spheroids or organoids in drug testing and precision medicine has led to significant advancements in how cancer a... YT Xin,TT Ong,KH Chow - 《World Scientific Annual Review of...
Patient-derived tumour organoids (PDOs) have revolutionised our understanding of cancer biology and the applications of personalised therapies. These advancements are principally ascribed to the ability of PDOs to consistently recapitulate and maintain the genomic, proteomic and morphological characteristics ...
Kevin S. Kolahi, Michitaka Nakano, Calvin J. KuoView PDFHighlights Summary Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. He...
Patient-derived organoids (PDOs) established from tissues from various tumor types gave the foundation of ex vivo models to screen and/or validate the activity of many cancer drug candidates. Due to their phenotypic and genotypic similarity to the tumor
organoid regions, causing their faster growth, while the overall growth pattern of organoids with diverse shapes tends to reduce interfacial tension at the organoid-hydrogel interface. In addition to the formation of organoid...
Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells and have predictive value supporting personalized medicine. Here we describe a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on a heterogeneous colorectal cancer PDO biobank and paired...